SynthesisBMC musculoskeletal disorders2026
Molecular endotypes in musculoskeletal disorders: a systematic review.
Synthesis in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMusculoskeletal (MSK) disorders are highly heterogeneous and have diverse cellular and molecular pathobiological mechanisms, termed "endotypes". This systematic review aimed to summarize current knowledge of molecular endotypes in MSK disorders.
methodsThis review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). Five databases including PubMed, Web of Science, Scopus, Ovid Medline, and Embase were searched for publications on molecular endotypes of MSK disorders classified by the International Classification of Diseases 11th Revision (ICD-11) that were published prior to September 1st, 2024. Articles were included if they were peer-reviewed original research articles on adult-onset human MSK disorder molecular endotypes/subtypes that used directly collected human specimen, in English language, and had full text available. Citations of the included studies were also screened manually using the same inclusion criteria.
resultsOur search identified 44,660 unique records and 34 eligible studies were included. The majority of these studies focused on osteoarthritis (OA, n = 14) and rheumatoid arthritis (RA, n = 12), with a small number of studies focused on other MSK conditions. In OA, high- and low-inflammation clusters were consistently identified using different types of samples, and high- and low-pain clusters were observed in several other studies. In RA, endotypes with different levels of inflammation markers or treatment responses were reported in several studies, and one study reported that RA patients displayed two different dysbiotic microbiota patterns which corresponded to different responses to treatments.
conclusionsMSK endotype research is still in its early stage. More endotype studies on MSK disorders are needed to assist in designing clinical trials and developing personalized therapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.